Appointment dossier — Squamous Cervical Carcinoma

Compounds studied in Squamous Cervical Carcinoma

• Cisplatin — Human evidence · 1 positive · PMID 23151423
• Topotecan — Human evidence · 1 positive · PMID 23151423
• Trastuzumab Deruxtecan — Human evidence · 1 positive · PMID 39639215
• Trastuzumab-Deruxtecan (T-Dxd) — Human evidence · 1 positive · PMID 39639215
• Pembrolizumab — Animal evidence · 1 positive · PMID 37469254

“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.

Open recruiting trials (18)

• NCT07733830 · Phase 2 — Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC (China)
• NCT06657222 · Phase 1 / Phase 2 — First in Human Study of TUB-030 in Patients With Advanced Solid Tumors (United States)
• NCT07039162 · Phase 2 — Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma (Taiwan)
• NCT05269381 · Phase 1 / Phase 2 — Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (United States)
• NCT07169734 · Phase 1 / Phase 2 — A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors (United States)
• NCT07348211 · Phase 1 — First in Human Study of SIM0610 in Solid Tumors (China)
• NCT05107674 · Phase 1 — A Study of NX-1607 in Adults With Advanced Malignancies (United States)
• NCT07090499 · Phase 1 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors (United States)
• NCT04135664 · Phase 3 — Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma (China)
• NCT07580300 · Phase 3 — Proton Versus Photon Therapy in Head and Neck Squamous Cell Carcinomas. (Norway)
• NCT04973306 · Phase 2 / Phase 3 — Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC (China)
• NCT06676449 · Phase 3 — TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC (China)
• NCT07026474 · Phase 3 — Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC (Germany)
• NCT06860971 · Phase 3 — A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma (China)
• NCT06782412 · Phase 2 / Phase 3 — Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types (Belgium)
• NCT06343870 · Phase 3 — Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME) (Brazil)
• NCT06752239 · Phase 3 — Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC (China)
• NCT07457346 · Phase 2 — A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer (China)

Most-relevant first: trials that name Squamous Cervical Carcinoma, then broader trials you may still qualify for. 647 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.

Financial help to look into

• PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
• HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
• CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
• Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
• NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/

For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.

Questions to ask your oncologist

1. I've read that Cisplatin has been studied in people for Squamous Cervical Carcinoma — what's the evidence, and is it an option or available in a trial for me?
2. I've read that Topotecan has been studied in people for Squamous Cervical Carcinoma — what's the evidence, and is it an option or available in a trial for me?
3. I've read that Trastuzumab Deruxtecan has been studied in people for Squamous Cervical Carcinoma — what's the evidence, and is it an option or available in a trial for me?
4. Of the open trials I found (for example NCT07733830), am I eligible for any — here or at a larger cancer center?
5. What is my exact diagnosis — the type, subtype, stage, and grade?
6. Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
7. Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
8. What is the goal of treatment for me — cure, long-term control, or comfort?
9. What are all of my standard treatment options, and what does each one involve?
10. What is the realistic benefit of each option, in actual numbers?
11. What are the most common and the most serious side effects, and how are they managed?
12. How will we know if treatment is working, and how often will I be scanned or tested?
13. If the first treatment doesn't work, what are the next options?
14. Are there gentler options if I want to prioritize quality of life?
15. Am I eligible for any clinical trials — here or at a larger/academic cancer center?
16. Is my case reviewed by a multidisciplinary tumor board?
17. Would a second opinion at a center that treats my cancer often be worthwhile?
18. Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
19. Which symptoms are emergencies, and who do I call after hours?
20. Should I see palliative or supportive care alongside my treatment?
21. How will treatment affect my daily life, work, and (if it matters to me) fertility?
22. What can I safely do myself — diet and activity — and is anything I'm taking risky?